LEXX - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the company’s proprietary DehydraTECH-CBD. DehydraTECH is a patented drug-delivery formulation and processing platform technology developed by Lexaria. The company noted that in addition to the three positive outcomes reported earlier — weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels — the study has indicated a reduction in blood glucose levels and improvements in kidney function. These results were gathered after the company undertook a further round of analysis to explore additional study outcomes; the additional analysis included using an alternate blood glucose assay detection system with higher detection sensitivity. The company also reported updates on two of its applied R&D programs:DEM-A22-1 and EPIL-A21-1. Lexaria’s DEM-A22-1 is a study designed to investigate whether DehydraTECH-CBD enables any procognitive performance enhancements with potential use in dementia treatment.
The company noted that the findings from this study were “generally unremarkable and several unexpected study complications may have muted efficacy distinction ability.” The EPIL-A21-1 was designed to evaluate the effectiveness of LEXX’s DehydraTECH-CBD compared to one of the world’s leading anti-seizure medications, Epidiolex(R), in reducing seizure activity. Initial findings from the study seemed to demonstrate that DehydraTECH-CBD had effectiveness at lower doses and with greater rapidity than Epidiolex. In the past few months, Lexaria has also completed a final study under its EPIL-A21-1 program that looked at establishing dosage amounts. “This ED50 study was designed with an objective to hopefully corroborate Lexaria’s prior MES experimental findings,” the company states in the press release. “Lexaria is pleased to confirm that the outcome demonstrated that DehydraTECH-CBD was most effective at a dose of 75 mg/Kg, also as previously reported from the initial round of work in this animal model, which compared favorably to Epidiolex that generally required a higher dose of 100 mg/Kg to achieve comparable findings.”
To view the full press release, visit https://ibn.fm/zHEfs
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 30 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.